Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10596427 | Bioorganic & Medicinal Chemistry Letters | 2012 | 9 Pages |
Abstract
Obesity is a global epidemic associated with multiple severe diseases. Several pharmacotherapies have been investigated including the melanin concentrating hormone (MCH) and its receptor 1. The development of MCHR1 antagonists are described with a specific perspective on different chemotypes investigated in efforts to overcome hERG liabilities while having orally active, potent and selective compounds with sufficient brain penetration. A chemometric comparison of â¼2000 diverse MCHR1 and â¼1000 diverse hERG ligands underline the structural similarities. A binding pocket analysis of a MCHR1 model and recent X-ray structures of GPCRs invoked in selectivity issues indicate a way to support future drug design.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Thomas Högberg, Thomas M. Frimurer, Pradip K. Sasmal,